Literature DB >> 25377794

From Chemotherapy-Induced Emesis to Neuroprotection: Therapeutic Opportunities for 5-HT3 Receptor Antagonists.

Gohar Fakhfouri1,2, Kazem Mousavizadeh3, Sharam Ejtemaei Mehr4, Ahmad Reza Dehpour4, Mohammad Reza Zirak5, Jean-Eric Ghia6, Reza Rahimian7.   

Abstract

5-HT3 receptor antagonists are extensively used as efficacious agents in counteracting chemotherapy-induced emesis. Recent investigations have shed light on other potential effects (analgesic, anxiolytic, and anti-psychotic). Some studies have reported neuroprotective properties for the 5-HT3 receptor antagonists in vitro and in vivo. When administered to Aβ-challenged rat cortical neurons, 5-HT3 receptor antagonists substantially abated apoptosis, elevation of cytosolic Ca(2), glutamate release, reactive oxygen species (ROS) generation, and caspase-3 activity. In addition, in vivo studies show that 5-HT3 receptor antagonists possess, alongside their anti-emetic effects, notable immunomodulatory properties in CNS. We found that pretreatment with tropisetron significantly improved neurological deficits and diminished leukocyte transmigration into the brain, TNF-α level, and brain infarction in a murine model of embolic stroke. Our recent investigation revealed that tropisetron protects against Aβ-induced neurotoxicity in vivo through both 5-HT3 receptor-dependent and -independent pathways. Tropisetron, in vitro, was found to be an efficacious inhibitor of the signaling pathway leading to the activation of pro-inflammatory NF-κB, a transcription factor pivotal to the upregulation of several neuroinflammatory mediators in brain. This mini review summarizes novel evidence concerning effects of 5-HT3 antagonists and their possible mechanisms of action in ameliorating neurodegenerative diseases including Alzheimer, multiple sclerosis, and stroke. Further, we discuss some newly synthesized 5-HT3 receptor antagonists with dual properties of 5-HT3 receptor blockade/alpha-7 nicotinic receptor activator and their potential in management of memory impairment. Since 5-HT3 receptor antagonists possess a large therapeutic window, they can constitute a scaffold for design and synthesis of new neuroprotective medications.

Entities:  

Keywords:  5-HT3 receptor antagonist; Anti-inflammatory; Neurodegeneration; Neuroinflammation; Neuroprotective

Mesh:

Substances:

Year:  2014        PMID: 25377794     DOI: 10.1007/s12035-014-8957-5

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  74 in total

Review 1.  5-HT receptor regulation of neurotransmitter release.

Authors:  Klaus B Fink; Manfred Göthert
Journal:  Pharmacol Rev       Date:  2007-12       Impact factor: 25.468

2.  The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model.

Authors:  Patricia Spilman; Olivier Descamps; Olivia Gorostiza; Clare Peters-Libeu; Karen S Poksay; Alexander Matalis; Jesus Campagna; Alexander Patent; Rammohan Rao; Varghese John; Dale E Bredesen
Journal:  Brain Res       Date:  2013-12-31       Impact factor: 3.252

3.  Dose-related impairment of spatial learning by intrahippocampal scopolamine: antagonism by ondansetron, a 5-HT3 receptor antagonist.

Authors:  M Carli; R Luschi; R Samanin
Journal:  Behav Brain Res       Date:  1997-01       Impact factor: 3.332

Review 4.  Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets.

Authors:  Dénes Zádori; Gábor Veres; Levente Szalárdy; Péter Klivényi; József Toldi; László Vécsei
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 5.  Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis.

Authors:  E N Benveniste
Journal:  J Mol Med (Berl)       Date:  1997-03       Impact factor: 4.599

6.  Tropisetron ameliorates ischemic brain injury in an embolic model of stroke.

Authors:  Reza Rahimian; Ali Daneshmand; Shahram Ejtemaei Mehr; Anita Barzegar-Fallah; Sanaz Mohammadi-Rick; Gohar Fakhfouri; Alireza P Shabanzadeh; Ahmad Reza Dehpour
Journal:  Brain Res       Date:  2011-03-27       Impact factor: 3.252

7.  Failure of ondansetron in treating cerebellar tremor in MS patients--an open-label pilot study.

Authors:  J Gbadamosi; C Buhmann; A Moench; C Heesen
Journal:  Acta Neurol Scand       Date:  2001-11       Impact factor: 3.209

Review 8.  Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease.

Authors:  Rodrigo A Fuentealba; Ginny Farias; Jessica Scheu; Miguel Bronfman; María Paz Marzolo; Nibaldo C Inestrosa
Journal:  Brain Res Brain Res Rev       Date:  2004-12

9.  5-Hydroxytryptamine3 receptors sited on cholinergic axon terminals of human cerebral cortex mediate inhibition of acetylcholine release.

Authors:  G Maura; G C Andrioli; P Cavazzani; M Raiteri
Journal:  J Neurochem       Date:  1992-06       Impact factor: 5.372

10.  Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia.

Authors:  H Tohgi; T Abe; S Takahashi; M Kimura; J Takahashi; T Kikuchi
Journal:  Neurosci Lett       Date:  1992-07-06       Impact factor: 3.046

View more
  9 in total

1.  Contribution of Hippocampal 5-HT3 Receptors in Hippocampal Autophagy and Extinction of Conditioned Fear Responses after a Single Prolonged Stress Exposure in Rats.

Authors:  Zhong-Min Wu; Li-Hua Yang; Rong Cui; Gui-Lian Ni; Feng-Tian Wu; Yong Liang
Journal:  Cell Mol Neurobiol       Date:  2016-06-21       Impact factor: 5.046

2.  The effect of tropisetron on peripheral diabetic neuropathy: possible protective actions against inflammation and apoptosis.

Authors:  Amir Mohammad Ghazipour; Bagher Pourheydar; Roya Naderi
Journal:  Cell Stress Chaperones       Date:  2022-08-16       Impact factor: 3.827

Review 3.  Microglial Inflammatory-Metabolic Pathways and Their Potential Therapeutic Implication in Major Depressive Disorder.

Authors:  Reza Rahimian; Claudia Belliveau; Rebecca Chen; Naguib Mechawar
Journal:  Front Psychiatry       Date:  2022-06-16       Impact factor: 5.435

4.  Involvement of 5-Serotonin and Substance p Pathways in Dichroa Alkali Salt-Induced Acute Pica in Rats.

Authors:  Lina Ma; Sidi Li; Jian Li; Guangping Zhang; Hongping Hou; Zuguang Ye
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

Review 5.  The serotonergic system and cognitive function.

Authors:  Dubravka Švob Štrac; Nela Pivac; Dorotea Mück-Šeler
Journal:  Transl Neurosci       Date:  2016-05-09       Impact factor: 1.757

Review 6.  Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases.

Authors:  Giuseppe Di Giovanni; Dubravka Svob Strac; Montse Sole; Mercedes Unzeta; Keith F Tipton; Dorotea Mück-Šeler; Irene Bolea; Laura Della Corte; Matea Nikolac Perkovic; Nela Pivac; Ilse J Smolders; Anna Stasiak; Wieslawa A Fogel; Philippe De Deurwaerdère
Journal:  Front Neurosci       Date:  2016-11-24       Impact factor: 4.677

Review 7.  Tapping into 5-HT3 Receptors to Modify Metabolic and Immune Responses.

Authors:  Helen Irving; Ilona Turek; Christine Kettle; Nor Yaakob
Journal:  Int J Mol Sci       Date:  2021-11-02       Impact factor: 5.923

8.  Tropisetron Preconditioning Decreases Myocardial Biomarkers in Patients Undergoing Heart Valve Replacement Surgery.

Authors:  Di Yu; Xingrui Gong; Yufei Zhang; Qing Li; Mazhang Zhang
Journal:  Front Med (Lausanne)       Date:  2022-03-29

Review 9.  Serotonin, neural markers, and memory.

Authors:  Alfredo Meneses
Journal:  Front Pharmacol       Date:  2015-07-21       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.